Good Manufacturing Practices are fundamental to product quality in both the Canadian Natural Health Product and U.S. dietary supplement industries. However, the requirements are not interchangeable. In the United States, dietary supplement manufacturers follow FDA’s current Good Manufacturing Practice requirements under 21 CFR Part 111. In Canada, Natural Health Products are governed by Part 3 of the Natural Health Products Regulations, interpreted through Health Canada’s GUI-0158. Both frameworks require controlled operations, qualified personnel, documented procedures, testing, traceability, and independent quality oversight. The differences lie primarily in regulatory structure, terminology, licensing, quality roles, testing, stability, documentation, and supply-chain responsibilities.
For companies manufacturing or selling dietary supplements in the United States and Natural Health Products (NHPs) in Canada, GMP compliance affects product release, supplier oversight, testing, documentation, storage, distribution, importing, complaint handling, recalls, and whether a product can remain on the market.
The terminology can create confusion. FDA uses current Good Manufacturing Practice, or cGMP, for dietary supplements. Health Canada generally uses Good Manufacturing Practices, or GMP, for NHPs. That difference does not mean Canada follows an outdated or lower standard, nor is cGMP a voluntary premium level of GMP. Each term refers to the mandatory manufacturing framework used by its regulator.
Both frameworks are intended to ensure products are consistently manufactured, packaged, labelled, tested, held, and controlled in a manner that protects consumers. The differences are found in how each regulator structures and applies those expectations.
The “c” stands for current. FDA uses the term to emphasize that manufacturers must apply practices, controls, systems, and technologies that remain appropriate in light of current knowledge and manufacturing conditions. This does not require the newest or most expensive equipment. It requires systems that remain scientifically appropriate, effective, maintained, and capable of ensuring product quality.
For dietary supplements, FDA’s requirements are codified in 21 CFR Part 111. The regulation is organized into Subparts A through P and covers personnel, facilities, equipment, process controls, quality control, materials, manufacturing records, laboratory operations, packaging, holding, distribution, returned products, complaints, and records.
Health Canada does not normally add “current” to the name of its NHP framework. Nevertheless, its expectations also evolve. GUI-0158 Version 4 published on September 4, 2025, and effective as of March 4, 2026, expanded expectations concerning quality systems, management involvement, quality risk management, supplier oversight, self-inspection, stability, corrective and preventive action, and continual improvement.
FDA’s dietary supplement cGMP regulation applies to both domestic and foreign persons who manufacture, package, label, or hold dietary supplements for distribution in the United States. Foreign firms performing those activities for dietary supplements imported or offered for import into the United States are also subject to Part 111. Part 111 is a legally enforceable federal regulation that establishes explicit operational requirements for specifications, written procedures, production and process controls, testing, Master Manufacturing Records, Batch Production Records, quality control, investigations, and recordkeeping.
Canadian GMP requirements for NHPs are established in Part 3 of the Natural Health Products Regulations. GUI-0158 is Health Canada’s administrative guidance for interpreting and applying those requirements. If the guidance conflicts with the legislation, the legislation takes precedence.
The framework applies to manufacturing, packaging, labelling, importing, distributing, storing, and testing NHPs. Distribution, storage and testing are not independently licensable activities, but products must still be distributed and stored in accordance with Part 3.
| Area | FDA Dietary Supplement cGMP | Health Canada NHP GMP |
| Primary framework | 21 CFR Part 111 | Part 3 of the Natural Health Products Regulations and GUI-0158 |
| Activities covered | Manufacturing, packaging, labelling, and holding | Manufacturing, packaging, labelling, importing, distributing, storing, and testing |
| Site authorization | No NHP-style site licence under Part 111; separate registration requirements may apply | Manufacturing, packaging, labelling, and importing generally require an NHP site licence |
| Product authorization | No NPN-style pre-market product licence for conventional dietary supplements | Finished NHPs generally require a product licence and NPN or DIN-HM |
| Quality role | Designated quality control personnel with distinct and separate quality-control responsibilities | Designated Quality Assurance Person (QAP) and an independent quality function appropriate to the organization |
| Batch release | Quality control approves or rejects product for distribution | QAP reviews and approves each batch before sale |
| Specifications | Identity, purity, strength, composition, and contamination limits | Identity, quantity, purity, potency, and applicable physical, chemical, and microbiological criteria |
| Identity testing | At least one appropriate identity test or examination is generally required for each dietary ingredient lot | Testing must demonstrate compliance with approved specifications using scientifically justified controls |
| Supplier COAs | May be relied upon for certain non-identity component specifications after supplier qualification and periodic reconfirmation. A supplier COA ordinarily cannot replace the required identity test or examination for a dietary ingredient | May form part of raw-material or finished-product approval. Canadian importers must review a COA for each imported finished-product lot, and any reduced or rotational testing program must be scientifically justified and controlled |
| Manufacturing records | Explicit Master Manufacturing Record and Batch Production Record requirements | Master production documents, batch records, specifications, SOPs, and release records |
| Stability | Part 111 does not require an expiry date or a standalone stability program. However, FDA states that any expiry, shelf-life or “best if used by” date placed on the product should be supported by data | Section 52 requires manufacturers and importers to determine the period during which the NHP will maintain the required quality characteristics. GUI-0158 expects this to be supported through a documented stability program |
| Quality system | Extensive written procedures and controls; no express quality-manual requirement | GUI-0158 expects a documented quality-management system proportionate to the operation, including a quality manual or equivalent, management involvement, supplier and outsourced-activity oversight, quality risk management, self-inspection and continual improvement |
| Foreign supply chain | Foreign firms performing covered manufacturing, packaging, labelling or holding activities are subject to Part 111. U.S. importers may also have Foreign Supplier Verification Program obligations, including modified requirements for dietary supplements under 21 CFR 1.511 | Importers must demonstrate foreign sites meet Canadian GMP or equivalent requirements |
Despite their differences, both frameworks are built on the same principle: quality cannot be tested into a finished product after manufacturing. It must be built into the systems that produce and control it.
Personnel must be qualified for the responsibilities they perform. Training should be role-specific, completed before independent work, updated when procedures or responsibilities change, and documented. Part 111 requires personnel to be qualified by education, training or experience and requires documentation of training. GUI-0158 places additional emphasis on demonstrating that personnel remain qualified and competent for their assigned responsibilities. Suitable premises and equipment
Facilities and equipment must be designed, maintained, cleaned, and operated to prevent contamination and mix-ups. Controls may include workflow, sanitation, pest control, environmental conditions, calibration, maintenance, and cross-contamination prevention.
Both frameworks require extensive written procedures, although the specific mandatory procedures are not identical. Common areas include personnel and training, sanitation, equipment, receiving and material control, manufacturing, packaging and labelling, laboratory operations, holding, returned products, complaints and recordkeeping.
GUI-0158 also expressly addresses documented supplier and outsourced-activity oversight, change control, CAPA, self-inspection, quality risk management and recall systems. Part 111 does not itself require a written recall procedure, although FDA recommends that companies establish one and separate statutory recall obligations may still apply.
Manufacturers must define measurable acceptance criteria for materials and finished products. Testing must be scientifically appropriate and supported by suitable methods, sampling plans, and records.
Appropriately qualified personnel must approve or reject materials, procedures, deviations, test results, and finished products. Records must allow the company to reconstruct how each batch was manufactured, tested, packaged, reviewed, and released.
Part 111 is a detailed operational regulation with separate subparts for personnel, facilities, equipment, controls, quality, materials, records, laboratories, packaging, holding, returns, and complaints. Canada places mandatory requirements in Part 3 and uses GUI-0158 to explain intent, interpretation, and acceptable evidence. Health Canada may consider an alternative approach when it is equal to or more stringent than the guide or is supported by appropriate scientific rationale.
Canada integrates GMP with site licensing and product licensing. Parties conducting licensable activities generally require a site licence, and finished NHPs generally require an NPN or DIN-HM. The United States does not use a directly equivalent product-licensing model for conventional dietary supplements. Canadian change control must therefore consider the quality system, product licence, site licence, authorized formulation, and approved specifications.
Under Part 111, quality control personnel review and approve or reject processes, specifications, procedures, testing, deviations, supplier decisions, records, and product disposition. FDA also requires personnel performing quality-control operations to have QC responsibilities that are distinct and separate from their other operational responsibilities. Health Canada identifies a QAP with suitable training, experience, technical knowledge, and authority. The QAP is central to the NHP quality system and must approve each batch before sale. GUI-0158 further emphasizes that the QAP’s quality decisions must remain independent from production, sales, marketing and other potential conflicts of interest
Part 111 generally requires at least one appropriate identity test or examination for each dietary ingredient lot unless FDA grants an exemption. A supplier COA normally does not replace this requirement. Canada does not use the same Part 111 rule requiring an identity test or examination for every dietary-ingredient lot. However, raw-material lots must still be evaluated against established specifications, and the finished NHP must comply with its approved specifications. GUI-0158 permits approaches such as reduced testing, rotational testing and quantification by input only where the applicable conditions and scientific justifications are satisfied.
Section 52 of the Natural Health Products Regulations requires manufacturers and importers to determine the period during which the product will maintain the specified quality characteristics under its recommended storage conditions. GUI-0158 translates this obligation into expectations for a documented stability program, including appropriate protocols, data and ongoing review. Part 111 does not contain an equivalent stand-alone stability section, although any stated shelf life should be scientifically supportable and product specifications must remain appropriate.
GUI-0158 expressly calls for a defined quality system, quality manual or equivalent, management involvement, supplier oversight, control of outsourced activities, self-inspections, quality audits, risk management, and continual improvement. Although many of these elements are articulated in guidance rather than repeated word-for-word in Part 3, they represent Health Canada’s current interpretation of an adequately designed and implemented NHP quality system. Part 111 contains many supporting controls but does not present them through the same overarching quality-management model.
Canadian importers must ensure foreign manufacturing, packaging, and labelling sites meet Canadian GMP or equivalent requirements and must maintain supporting evidence. They may also carry responsibilities for release, testing, stability, complaints, traceability, and recalls. In the United States, foreign manufacturers performing covered operations are subject to Part 111, while the U.S. importer may also be subject to FSVP requirements. Dietary supplement importers can qualify for modified FSVP requirements under 21 CFR 1.511, depending on whether the importer or its customer establishes and verifies the applicable Part 111 specifications.
Companies do not necessarily need two disconnected quality systems. A well-designed integrated system can address the shared requirements while incorporating jurisdiction-specific controls.
GMP and cGMP share a common purpose: ensuring products are consistently manufactured and controlled to meet defined quality requirements. The difference is not that the United States requires a current standard while Canada accepts an older one.
FDA’s Part 111 establishes a detailed production and process-control framework with explicit requirements for identity testing, specifications, quality-control operations, Master Manufacturing Records, Batch Production Records, and supporting documentation. Health Canada combines mandatory GMP requirements with site licensing, product licensing, importer accountability, QAP batch release, stability obligations, and a quality-management and risk-based model under GUI-0158.
The strongest approach for companies selling in both countries is an integrated quality system that applies consistent global controls while deliberately addressing each jurisdiction’s unique requirements.
For many organizations, the challenge is not recognizing that GMP and cGMP matter. It is translating regulatory requirements into a quality system that works in daily operations and stands up to regulatory scrutiny.
dicentra supports dietary supplement and NHP companies with practical, risk-based compliance services for 21 CFR Part 111 and Health Canada’s GUI-0158, including:
Training is also critical to sustained compliance. Both frameworks require appropriately qualified and trained personnel and supporting training records.